Research Reports Initiation on Medical Equipment Stocks -- Lantheus, Cynosure, Natus Medical, and NovoCure

NEW YORK, February 23, 2017 /PRNewswire/ --

On Wednesday, February 22, 2017, US markets saw a mixed end of day as four out of nine sectors finished the trading sessions in green, four closed in red, and one sector managed a flat closing. Major US indices were also mixed at the close of yesterday's session. The NASDAQ Composite ended the day at 5,860.63, slightly down by 0.09%; the Dow Jones Industrial Average edged 0.16% higher, to finish at 20,775.60; and the S&P 500 closed at 2,362.82, down 0.11%. This Thursday morning, Stock-Callers.com looks at the performance of these four Medical Appliances & Equipment stocks: Lantheus Holdings Inc. (NASDAQ: LNTH), Cynosure Inc. (NASDAQ: CYNO), Natus Medical Inc. (NASDAQ: BABY), and NovoCure Ltd (NASDAQ: NVCR). You can access our complimentary research reports on these stocks now at:

http://stock-callers.com/registration

Lantheus  

North Billerica, Massachusetts headquartered Lantheus Holdings Inc.'s stock surged 29.95%, to close the day at $12.15. The stock recorded a trading volume of 1.79 million shares, which was above its three months average volume of 293,420 shares. Lantheus Holdings' shares have rallied 42.11% in the last one month, 31.35% in the previous three months, and 421.46% in the past one year. The Company's shares are trading 36.65% and 75.02% above its 50-day and 200-day moving averages, respectively. Shares of the Company, which develops, manufactures, and commercializes diagnostic medical imaging agents and products for the diagnosis and treatment of cardiovascular and other diseases worldwide, are trading at a PE ratio of 14.48. Additionally, the stock has a Relative Strength Index (RSI) of 80.97. Visit us today and download your complete report on LNTH for free at:

http://stock-callers.com/registration/?symbol=LNTH

Cynosure  

On Wednesday, shares in Westford, Massachusetts headquartered Cynosure Inc. ended the session 0.30% higher at $66.30 with a total volume of 1.62 million shares traded. Cynosure's shares have gained 41.82% in the last one month and 51.54% in the previous three months. Furthermore, the stock has surged 69.52% in the past one year. Shares of the Company, which develops, manufactures, and markets aesthetic treatment systems for plastic surgeons, dermatologists, and other medical practitioners, are trading at a PE ratio of 102.00. The stock is trading 35.40% above its 50-day moving average and 35.00% above its 200-day moving average. Moreover, the Company's shares have an RSI of 77.01.

On February 14^th, 2017, research firm Maxim Group downgraded the Company's stock rating from 'Buy' to 'Hold', with a target price of $66 per share. The complimentary research report on CYNO can be accessed at:

http://stock-callers.com/registration/?symbol=CYNO

Natus Medical  

On Wednesday, shares in Pleasanton, California headquartered Natus Medical Inc. recorded a trading volume of 285,355 shares. The stock ended the day 0.92% lower at $37.55. Shares of the Company, which designs, manufactures, and markets newborn care and neurology healthcare products and services worldwide, are trading at a PE ratio of 28.77. Natus Medical's stock has advanced 5.18% in the past one year. The Company is trading above its 50-day moving average by 2.13%. Furthermore, Natus Medical's shares have an RSI of 55.59.

On February 02^nd, 2017, research firm Raymond James downgraded the Company's stock rating from 'Outperform' to 'Market Perform'. Register for free on Stock-Callers.com and download the PDF research report on BABY at:

http://stock-callers.com/registration/?symbol=BABY

NovoCure  

Saint Helier, Channel Islands-based NovoCure Ltd's stock finished Wednesday's session 2.05% lower at $7.15 with a total volume of 223,296 shares traded. NovoCure's shares have gained 11.72% in the past one month. The Company's shares are trading below its 50-day and 200-day moving averages by 5.06% and 19.84%, respectively. Shares of NovoCure, which develops and commercializes treatment for solid tumor cancers therapy called the tumor treating fields, have an RSI of 48.86. Get free access to your research report on NVCR at:

http://stock-callers.com/registration/?symbol=NVCR

--

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://stock-callers.com/legal-disclaimer/

CONTACT 
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA